QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
NASDAQ:ANIP

ANI Pharmaceuticals (ANIP) Stock Forecast, Price & News

$58.19
-0.33 (-0.56%)
(As of 09/25/2023 ET)
Compare
Today's Range
$57.54
$58.91
50-Day Range
$50.78
$64.61
52-Week Range
$30.53
$65.89
Volume
98,513 shs
Average Volume
120,036 shs
Market Capitalization
$1.18 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$71.67

ANI Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
23.2% Upside
$71.67 Price Target
Short Interest
Healthy
1.31% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.48
Upright™ Environmental Score
News Sentiment
0.37mentions of ANI Pharmaceuticals in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$26.96 M Sold Last Quarter
Proj. Earnings Growth
9.46%
From $3.17 to $3.47 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.55 out of 5 stars

Medical Sector

145th out of 961 stocks

Pharmaceutical Preparations Industry

45th out of 451 stocks


ANIP stock logo

About ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations, including extended release and combination products. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

ANIP Price History

ANIP Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Short Interest Update
ANI Pharmaceuticals (NASDAQ:ANIP) Earns "Buy" Rating from Guggenheim
Analyst Expectations for ANI Pharmaceuticals's Future
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
ANI Pharma: Slow And Steady Revenue Generator
ANI Pharma: Slow And Steady Revenue Generator
ANI Pharma granted FDA nod for generic Estradiol Gel
What Makes ANI (ANIP) a New Strong Buy Stock
Here's Why Momentum in ANI (ANIP) Should Keep going
What 4 Analyst Ratings Have To Say About ANI Pharmaceuticals
See More Headlines
Receive ANIP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ANIP Company Calendar

Last Earnings
8/09/2023
Today
9/25/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ANIP
Previous Symbol
NASDAQ:BPAX
Employees
600
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$71.67
High Stock Price Forecast
$73.00
Low Stock Price Forecast
$70.00
Forecasted Upside/Downside
+21.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-47,900,000.00
Pretax Margin
-2.62%

Debt

Sales & Book Value

Annual Sales
$316.39 million
Cash Flow
$4.07 per share
Book Value
$17.92 per share

Miscellaneous

Free Float
14,509,000
Market Cap
$1.20 billion
Optionable
Optionable
Beta
1.05
10 Best Stocks to Own in 2023 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Nikhil LalwaniMr. Nikhil Lalwani (Age 45)
    Pres, CEO & Director
    Comp: $1.31M
  • Mr. Stephen P. CareyMr. Stephen P. Carey (Age 52)
    Sr. VP of Fin. & CFO
    Comp: $751k
  • Mr. James G. Marken (Age 60)
    Sr. VP of Operations & Product Devel.
    Comp: $673.23k
  • Mr. Christopher K. Mutz (Age 51)
    Head of Rare Disease
    Comp: $565.17k
  • Mr. Ori Gutwerg (Age 49)
    Sr. VP of Generics
    Comp: $623.89k
  • Mr. Muthusamy Shanmugam MS R.Ph.Mr. Muthusamy Shanmugam MS R.Ph. (Age 55)
    Head of R&D, COO of Novitium Operations & Director
  • Ms. Meredith W. Cook (Age 49)
    Sr. VP, Gen. Counsel & Corp. Sec.
  • Mr. Chad Gassert (Age 47)
    Sr. VP of Corp. Devel. & Strategy
  • Ms. Krista L. Davis (Age 50)
    Chief HR Officer
  • Ms. Elizabeth Powell J.D.
    Chief Compliance Officer & Head of Legal of Rare Disease













ANIP Stock - Frequently Asked Questions

Should I buy or sell ANI Pharmaceuticals stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ANIP shares.
View ANIP analyst ratings
or view top-rated stocks.

What is ANI Pharmaceuticals' stock price forecast for 2023?

3 Wall Street analysts have issued 12-month target prices for ANI Pharmaceuticals' shares. Their ANIP share price forecasts range from $70.00 to $73.00. On average, they expect the company's share price to reach $71.67 in the next year. This suggests a possible upside of 21.7% from the stock's current price.
View analysts price targets for ANIP
or view top-rated stocks among Wall Street analysts.

How have ANIP shares performed in 2023?

ANI Pharmaceuticals' stock was trading at $40.23 at the start of the year. Since then, ANIP shares have increased by 46.4% and is now trading at $58.91.
View the best growth stocks for 2023 here
.

Are investors shorting ANI Pharmaceuticals?

ANI Pharmaceuticals saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 264,800 shares, a decrease of 7.5% from the August 15th total of 286,200 shares. Based on an average daily trading volume, of 156,800 shares, the short-interest ratio is currently 1.7 days.
View ANI Pharmaceuticals' Short Interest
.

When is ANI Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our ANIP earnings forecast
.

How were ANI Pharmaceuticals' earnings last quarter?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) released its quarterly earnings results on Wednesday, August, 9th. The specialty pharmaceutical company reported $1.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.64. The specialty pharmaceutical company earned $116.50 million during the quarter, compared to analyst estimates of $99.87 million. ANI Pharmaceuticals had a negative net margin of 1.29% and a positive trailing twelve-month return on equity of 15.77%. The business's revenue was up 57.6% on a year-over-year basis. During the same period in the previous year, the company posted ($0.05) EPS.

What ETFs hold ANI Pharmaceuticals' stock?

ETFs with the largest weight of ANI Pharmaceuticals (NASDAQ:ANIP) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (PILL).

What guidance has ANI Pharmaceuticals issued on next quarter's earnings?

ANI Pharmaceuticals issued an update on its FY23 earnings guidance on Wednesday, August, 30th. The company provided earnings per share guidance of $3.62-4.11 for the period, compared to the consensus EPS estimate of $3.97. The company issued revenue guidance of $425-445 million, compared to the consensus revenue estimate of $442.79 million.

What is Arthur Przbyl's approval rating as ANI Pharmaceuticals' CEO?

5 employees have rated ANI Pharmaceuticals Chief Executive Officer Arthur Przbyl on Glassdoor.com. Arthur Przbyl has an approval rating of 100% among the company's employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at ANI Pharmaceuticals to a friend.

What other stocks do shareholders of ANI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Broadcom (AVGO), Cisco Systems (CSCO), Exelixis (EXEL) and Intel (INTC).

What is ANI Pharmaceuticals' stock symbol?

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

Who are ANI Pharmaceuticals' major shareholders?

ANI Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (11.87%), Rubric Capital Management LP (4.71%), Dimensional Fund Advisors LP (3.03%), William Blair Investment Management LLC (3.00%), Deep Track Capital LP (2.53%) and State Street Corp (2.71%). Insiders that own company stock include Antonio R Pera, Chad Gassert, James G Marken, Jeanne Thoma, Meridian Venture Partners Ii L, Muthusamy Shanmugam, Nikhil Lalwani, Ori Gutwerg, Patrick D Walsh and Thomas Haughey.
View institutional ownership trends
.

How do I buy shares of ANI Pharmaceuticals?

Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ANI Pharmaceuticals' stock price today?

One share of ANIP stock can currently be purchased for approximately $58.91.

How much money does ANI Pharmaceuticals make?

ANI Pharmaceuticals (NASDAQ:ANIP) has a market capitalization of $1.20 billion and generates $316.39 million in revenue each year. The specialty pharmaceutical company earns $-47,900,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis.

How many employees does ANI Pharmaceuticals have?

The company employs 600 workers across the globe.

How can I contact ANI Pharmaceuticals?

ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The official website for the company is www.anipharmaceuticals.com. The specialty pharmaceutical company can be reached via phone at (218) 634-3500, via email at ir@anipharmaceuticals.com, or via fax at 218-634-3540.

This page (NASDAQ:ANIP) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -